| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-103-1-32 |
| P698 | PubMed publication ID | 4003987 |
| P50 | author | Michael Reiss | Q56547220 |
| P2093 | author name string | J M Kirkwood | |
| C A Davis | |||
| M Reiss | |||
| M S Ernstoff | |||
| R Ferraresi | |||
| S A Rudnick | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 32-36 | |
| P577 | publication date | 1985-07-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers | |
| P478 | volume | 103 |
| Q35000575 | A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha |
| Q47785753 | A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma |
| Q36844314 | Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach |
| Q36292432 | Adjuvant therapy for melanoma: How should we respond to high-dose interferon? |
| Q34979790 | Adjuvant therapy of malignant melanoma |
| Q39190801 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma |
| Q24685049 | Biological response modifiers in cancer |
| Q37854629 | Biotherapeutic bioanalysis: a multi-indication case study review |
| Q37908998 | Cancer immunotherapy--revisited |
| Q39958332 | Cancer immunotherapy. |
| Q41689551 | Cardiovascular toxicity with cancer chemotherapy |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q40638811 | Cisplatin, interleukin-2, interferon-alpha and tamoxifen in metastatic melanoma. A phase II study |
| Q36190624 | Clinical and immunologic basis of interferon therapy in melanoma |
| Q69996775 | Dermatologic therapy: December 1984 through December 1985 |
| Q40161836 | Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha |
| Q38504023 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. |
| Q46201864 | Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma |
| Q36138329 | Gene-expression profiling in vaccine therapy and immunotherapy for cancer |
| Q35009889 | HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future |
| Q37286548 | Homozygous deletions within human chromosome band 9p21 in melanoma |
| Q35572008 | IFN-α in the treatment of melanoma |
| Q37070203 | Immunomodulatory cytokines as therapeutic agents for melanoma |
| Q67702761 | Immunotherapy of Malignant Melanoma |
| Q36243536 | Immunotherapy of cancer in 2012. |
| Q54313285 | In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. |
| Q46120320 | Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers |
| Q38190337 | Interferon for treatment: the dust settles |
| Q45834652 | Interferon therapy of chronic hepatitis B virus infection in Chinese |
| Q48669473 | Interferon-Related Leukoencephalopathy in a Patient with Renal Cell Carcinoma |
| Q40485713 | Interferon-alpha in malignant and viral diseases. A review |
| Q33836075 | Interferon-alpha therapy for melanoma |
| Q34012443 | Interferons and interferon regulatory factors in malaria |
| Q38210046 | Interferons: biological and clinical effects |
| Q40645833 | Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: a feasibility study |
| Q51740945 | Intralesional recombinant alpha-interferon for localized prostate cancer: a pilot study with follow-up of >10 years. |
| Q33374105 | Malignant melanoma: Primary presentation in bone marrow and lymph node |
| Q57797941 | Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire |
| Q37920836 | Neoadjuvant therapy for high-risk bulky regional melanoma |
| Q92485631 | Neoadjuvant therapy of locally/regionally advanced melanoma |
| Q39654683 | Nonsurgical treatments for skin cancer: retinoids and alpha-interferon |
| Q35763344 | Pathophysiology of cancer-related fatigue |
| Q67677208 | Role of Interferons in the Thearpy of Melanoma |
| Q41133458 | Seizures during alpha interferon therapy |
| Q33693906 | State of melanoma: an historic overview of a field in transition |
| Q48477930 | Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. |
| Q74552352 | Systemic therapy in melanoma |
| Q64087803 | The Clinical Trial Landscape for Melanoma Therapies |
| Q38171061 | The antitumor effects of interferon. |
| Q35058213 | The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. |
| Q37908142 | The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. |
| Q70839282 | The role of alpha interferon in the biomodulation of disease: preface |
| Q48376397 | The role of immunotherapy in oncology. |
| Q38208932 | The role of interferons in the treatment of malignant neoplasms |
| Q69723270 | Treatment of metastatic malignant melanoma with recombinant interferon alpha 2 |
Search more.